Afrezza (insulin human) Inhalation Powder

About MannKind Corp

MannKind Corporation is a public biopharmaceutical company pioneering inhaled therapeutic delivery systems, primarily for diabetes and pulmonary diseases. Its flagship product, Afrezza, is an FDA-approved rapid-acting inhaled insulin that offers a needle-free alternative for prandial insulin. The company leverages its proprietary Technosphere® platform to develop novel inhaled formulations, with a pipeline targeting endocrine disorders and orphan lung conditions like pulmonary arterial hypertension and pulmonary fibrosis. MannKind's strategy combines commercial execution of Afrezza with pipeline advancement through internal R&D and strategic partnerships.

Therapeutic Areas